MAM
L&K Saatchi & Saatchi hires Rajeev Rakshit as president – North; ups Sanjeev Gauba
MUMBAI: As part of the organisation’s restructuring in Delhi, Law & Kenneth Saatchi & Saatchi has appointed Rajeev Rakshit as president – North.
On the other hand, the agency has promoted L&K Saatchi & Saatchi senior vice president – Delhi operations Sanjeev Gauba as executive vice president.
Law & Kenneth Saatchi & Saatchi CEO and managing partner Anil Nair said, “Rajeev will focus on growing the branch and organically exploring growth opportunity with our key clients. Sanjeev Gauba, who was our senior vice president of Delhi operations, is going to focus more on consolidation with our largest businesses in Delhi and has been promoted to executive vice president. With these two senior resources spearheading Delhi, I’m sure Law & Kenneth Saatchi & Saatchi Delhi will be the fastest growing agency in the market.”
Rakshit added, “With Delhi as a focus, the organisation has prioritised the office to be a key growth engine. With ambitious plans, I am looking forward to the challenges ahead. Also, with an extremely talented and motivated team already in place, this is a tremendous opportunity to manoeuvre it to greater success.”
Armed with 25 years of experience, Rakshit has previously worked with companies like HMV Saregama, Orchard (Leo Burnett), Everest Y&R, Publicis, Euro RSCG, McCann and Bates Clarion.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
